NHMRC Synergy Grant of $5M for CAR T cell therapy
Professor Ian Davis
A newly funded Monash University-led research program will investigate the potential of Chimeric Antigen Receptor T (CAR T) cell therapy, previously only effective in blood cancers, for the treatment of prostate cancer.
Prostate cancer is the most commonly diagnosed cancer1 in Australia and remains a leading cause of death worldwide2. At present, there is no cure for advanced prostate cancer.
A multi-disciplinary and multi-institutional team of researchers has been awarded a $5 million Synergy Grant from the National Health and Medical Research Council (NHMRC) to develop highly-tailored treatment regimens for prostate cancer, using next-generation CAR T cell therapy.